Fig. 7
From: MSH6 as a prognostic biomarker in bladder cancer and its correlation with immunity
Mutational signature of MSH6 in patients with bladder cancer in the TCGA cohort determined using the cBioPortal tool. (a) Type of MSH6 in patients with bladder cancer from the TCGA cohort and the frequency of mutation changes. (b) K‒M survival analysis of OS with or without MSH6 alterations. (c) MSH6 mutation sites in bladder cancer.
